Stock listing

OTC:NKGN NKGen Biotech Inc. Stock

Follow NKGen Biotech Inc. into a list and get an email when it puts out news.

Share price · OTC:NKGN

$0.0030 USD 0.0000 (0.0%)

Close on Nov 20, 2026

Past year -85.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.0030 – $0.0030 USDNov 20, 2026
Volume
1,500 sharesNov 20, 2026
Market cap
$391,807 USDAt the close on Nov 20, 2026 · price × 130.6M shares outstanding
52-week range
$0.0010 – $0.2000 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$21 USDMedian day 150 shares · 29 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
NKGen Biotech Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:NKGN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00300.00000.0%$0.0030$0.0030$0.00301,500
$0.00300.00000.0%$0.0030$0.0030$0.00303,100
$0.0030-0.0080-72.7%$0.0030$0.0030$0.00302,500
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01104,200
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01101,700
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01105,100
$0.01100.00000.0%$0.0110$0.0110$0.01102,500
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01101,500
$0.01100.00000.0%$0.0110$0.0110$0.0110300
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.0110+0.0010+10.0%$0.0110$0.0110$0.01101,600
$0.0100+0.0070+233.3%$0.0100$0.0100$0.0100500
$0.0030-0.0080-72.7%$0.0030$0.0030$0.003014,500
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.0110400
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01108,000
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01105,200
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.01100
$0.01100.00000.0%$0.0110$0.0110$0.0110200
$0.0110-0.0010-8.3%$0.0110$0.0110$0.01107,000
$0.01200.00000.0%$0.0120$0.0120$0.01200
$0.01200.00000.0%$0.0120$0.0120$0.012010,000
$0.01200.00000.0%$0.0120$0.0120$0.0120200
$0.01200.00000.0%$0.0120$0.0120$0.01200
$0.01200.00000.0%$0.0120$0.0120$0.01200
$0.01200.00000.0%$0.0120$0.0120$0.01202,200
$0.01200.00000.0%$0.0120$0.0120$0.01200
$0.0120+0.0100+500.0%$0.0110$0.0120$0.010048,200
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0020$0.0020$0.0020100
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0020$0.0020$0.002010,000
$0.00200.00000.0%$0.0020$0.0020$0.0020300
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0020$0.0020$0.0020400
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0020$0.0020$0.00201,900
$0.00200.00000.0%$0.0020$0.0020$0.00202,500
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.00200.00000.0%$0.0020$0.0020$0.00203,800
$0.0020-0.0001-4.8%$0.0020$0.0020$0.00201,500
$0.0021-0.0030-58.8%$0.0021$0.0021$0.00212,001
$0.0051+0.0001+2.0%$0.0051$0.0051$0.0051200
$0.00500.00000.0%$0.0050$0.0050$0.00500
$0.00500.00000.0%$0.0050$0.0050$0.00500
Ticker
OTC:NKGN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All NKGen Biotech Inc. news

NKGen Biotech Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
8 in the last 12 months · 31 in all · newest Nov 16, 2026 · oldest 2025
Decks
15 decks · latest March 2026

Valuation

Statements: Year to Dec 31, 2025 · price Nov 20, 2026

Enterprise value
$38.58M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
0.88

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
NKGen Biotech Inc. · OTC:NKGNUS$391,807US$38.58Mn/an/an/an/an/an/a0.88
Protagenic Therapeutics, Inc. · OTC:PTIXUS$687,879US$610,9700.1×n/an/a0.6×n/a0.0×1.21
Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABTUS$580,337−US$2.74Mn/an/an/a0.2×n/a0.0×0.46
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Jaguar Health, Inc. · NASDAQ:JAGXUS$527,406−US$1.48Mn/a−0.1×n/a0.0×−181.8%0.2×3.75
Altamira Therapeutics Ltd. · OTC:CYTOFUS$404,655US$400,900n/an/an/a0.1×n/a0.0×0.64
Vaxil Bio Ltd. · TSXV:VXLUS$319,522−US$4,0711.2×n/an/a0.4×n/a0.0×-0.16
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Median of the othersUS$362,089−US$205,5420.7×−0.1×0.2×−222.3%0.0×1.21

Team and board

OfficerRole
Denise ChuaSVP, Corporate Affairs

Events

QuarterResultsShare move
Q4 2025Jan 20, 20260.0%
Q3 2025Oct 8, 2025+100.0%
Quarter to Dec 31, 2024Mar 4, 2025
Q2 2024Sep 12, 2024 · After close
Q1 2024May 20, 2024 · After close
Q4 2022Mar 31, 2023
Q3 2022Nov 14, 2022
Q2 2022Aug 15, 2022
Q1 2022May 16, 2022
Q4 2021Mar 31, 2022
All 12 quarters
QuarterResultsShare move
Q3 2021Nov 15, 2021
Q2 2021Aug 16, 2021

Open Events

Decks

DeckKindSlidesDate
AD/PD 2026Conference21 slidesMarch 2026
Investor Presentation (January 2026)Investor deck29 slidesJanuary 2026
WCN 2025Conference32 slidesOctober 2025
ASGCT 28th Annual Meeting 2025Conference41 slidesMay 14, 2025
AD/PD 2025 International Conference on Alzheimer's and Parkinson's DiseasesConference20 slidesApril 2025
H.C. Wainwright 26th Annual Global Investment Conference 2024Conference60 slidesSep 9, 2024
Investor Presentation (September 2024)Investor deck39 slidesSeptember 2024
Allogeneic Cell Therapies Summit 2024Conference39 slidesJune 2024
AD/PD Drug Development Summit 2024Conference39 slidesApr 25, 2024
Technical Presentation (March 2024)Technical13 slidesMar 25, 2024
All 15 decks
DeckKindSlidesDate
Investor Presentation (February 2024)Investor deck36 slidesFebruary 2024
Graf Acquisition Corp. IV — SPAC Merger (July 2023)SPAC merger66 slidesJul 26, 2023
Graf Acquisition Corp. IV — SPAC Merger (July 2023)SPAC merger25 slidesJul 17, 2023
SPAC Merger (July 2023)SPAC merger59 slidesJuly 2023
Graf Acquisition Corp. IV — SPAC Merger (June 2023)SPAC merger50 slidesJun 1, 2023

Open Decks

Financings

RaiseDate
Funding (terms to be finalized)
Closed: US$17M raised
Buyers: AlpineBrook Capital GP 1 Limited (provided the majority of the $17 million funding); Dr. Paul Y. Song (provided the remainder of the funding)
Insiders: NKGen CEO Dr. Paul Y. Song provided part of the funding alongside AlpineBrook
Use of proceeds: Purchase of NKMax Co., Ltd. shares
Sep 9, 2025
Private placement of shares of common stock and warrants
Closed: US$2M raised · US$0.25 a share
Buyers: Japanese strategic investor ($2 million)
Use of proceeds: Resources to regain compliance with reporting obligations and listing standards
Jul 16, 2025
Private placement of shares of common stock and warrants
Closed: US$2.65M raised
Buyers: Paul Y. Song, M.D. ($2.65 million in shares of common stock and warrants)
Insiders: Chairman & CEO Paul Y. Song, M.D. invested $2.65 million cash in shares of common stock and warrants
Use of proceeds: Accelerate Phase 2 Alzheimer's trial, reduce payables, general working capital and public company compliance expenses
May 8, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2023FY2022FY2021
Revenue077.0K426.0K
Cost of revenue1.20M18.0K30.0K
Gross profit-1.20M59.0K396.0K
Research and development10.7M15.7M16.7M14.7M
Selling, general and administrative16.3M14.1M7.66M7.58M
Operating income-27.0M-29.7M-24.3M-21.9M
Depreciation and amortization1.31M1.20M1.21M1.24M
EBITDA-25.7M-28.5M-23.1M-20.6M
Interest expense2.72M745.0K2.31M1.31M
Income before tax-44.2M-82.9M-26.7M-23.3M
Income tax53.0K7.00K7.00K5.00K
Net income-44.3M-83.0M-26.8M-23.3M
Earnings per share, basic-1.54-5.38-1.25-1.08

Balance sheet

LineFY2025FY2023FY2022FY2021
Cash and equivalents26.0K117.0K351.0K
Receivables24.0K26.0K96.0K67.0K
Inventory-250.0K133.0K172.0K
Current assets24.0K1.93M350.0K612.0K
Property, plant and equipment15.9M17.4M
Total assets24.0K16.5M16.3M18.1M
Accounts payable11.0M975.0K1.71M
Current liabilities39.5M14.7M55.7M
Long-term debt9.93M
Total debt19.9M12.0M52.0M
Total liabilities75.2M14.8M56.1M
Shareholders' equity-58.7M1.56M-38.1M
Shares outstanding28.8M15.4M21.5M21.5M

Cash flow

LineFY2025FY2023FY2022FY2021
Cash from operations-20.9M-21.9M-22.6M-19.5M
Capital spending0-48.0K-163.0K-459.0K
Free cash flow-20.9M-22.0M-22.7M-20.0M
Cash from investing-13.0K-48.0K-163.0K-459.0K
Cash from financing20.9M22.2M22.5M20.2M
Change in cash1.70M159.0K-234.0K152.0K

Open Financials

Cap table

Built by 6ix from NKGen Biotech Inc.’s releases · as of Sep 9, 2025

Common shares
130,602,230
Fully diluted
130,602,230

Fully diluted

LineShares
Common shares130,602,230

Share count over time

CountShares
Nov 22, 2026130,602,230

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Meteora Capital, LLC2.76M2.1%US$165KJun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Paul Y. Song54.30%63.7MMay 5, 2025Schedule 13D
CFIC-2015 NV Family Investments, LLC47.20%63.2MMay 27, 2025Schedule 13D
PATHSTONE FAMILY OFFICE, LLC7.91%2.8MOct 17, 2024Schedule 13G
Meteora Capital, LLC6.13%2.76MMar 31, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Kathleen Scott
Other companies: ARS Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Nov 8, 2022); Dermata Therapeutics, Inc. (Director · Since at least Aug 12, 2021); Histogen Inc (Director · Nov 18, 2019 – Nov 18, 2019 · Past)
Director · Sep 29, 2023 – Dec 6, 2024 · Past
Denise ChuaSVP, Corporate Affairs · Since at least Sep 15, 2026
Marco GottardisDirector · May 23, 2024 – Jul 11, 2024 · Past
Paul Y SongChief Executive Officer · Sep 28, 2023 – May 5, 2025 · Past
Pierre GagnonChief Operating Officer · Sep 29, 2023 – Feb 12, 2024 · Past
Sangwoo ParkDirector · Sep 29, 2023 – Dec 13, 2023 · Past
Yong Man KimCSO and CIO · Sep 29, 2023 – Feb 12, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about NKGen Biotech Inc.